GT Biopharma Analyst Ratings
GT Biopharma Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/07/2023 | 651.88% | EF Hutton | → $2 | Reiterates | Hold → Hold |
| 06/05/2023 | 1779.69% | HC Wainwright & Co. | → $5 | Reiterates | Buy → Buy |
| 05/17/2023 | 1779.69% | HC Wainwright & Co. | → $5 | Reiterates | Buy → Buy |
| 05/16/2023 | 651.88% | EF Hutton | → $2 | Reiterates | Hold → Hold |
| 04/03/2023 | 1779.69% | HC Wainwright & Co. | → $5 | Reiterates | → Buy |
| 03/31/2023 | 651.88% | EF Hutton | → $2 | Reiterates | → Hold |
| 01/05/2023 | 651.88% | EF Hutton | → $2 | Initiates Coverage On | → Hold |
| 09/13/2022 | 1779.69% | HC Wainwright & Co. | $25 → $5 | Maintains | Buy |
| 05/24/2021 | 9298.46% | HC Wainwright & Co. | → $25 | Initiates Coverage On | → Buy |
| 04/13/2021 | 7794.71% | B. Riley Securities | → $21 | Initiates Coverage On | → Buy |
| 03/17/2021 | 9298.46% | Roth Capital | → $25 | Initiates Coverage On | → Buy |
| 日期 | 上行/下行 | 分析公司 | 目標價格變動 | 評級變動 | 之前/當前的評級 |
|---|---|---|---|---|---|
| 08/07/2023 | 651.88% | EF Hutton | → 2 美元 | 重申 | 按住 → 按住 |
| 06/05/2023 | 1779.69% | HC Wainwright & Co. | → 5 美元 | 重申 | 購買 → 購買 |
| 05/17/2023 | 1779.69% | HC Wainwright & Co. | → 5 美元 | 重申 | 購買 → 購買 |
| 05/16/2023 | 651.88% | EF Hutton | → 2 美元 | 重申 | 按住 → 按住 |
| 04/03/2023 | 1779.69% | HC Wainwright & Co. | → 5 美元 | 重申 | → 購買 |
| 03/31/2023 | 651.88% | EF Hutton | → 2 美元 | 重申 | → 按住 |
| 01/05/2023 | 651.88% | EF Hutton | → 2 美元 | 啓動覆蓋開啓 | → 按住 |
| 09/13/2022 | 1779.69% | HC Wainwright & Co. | 25 美元 → 5 美元 | 維護 | 購買 |
| 05/24/2021 | 9298.46% | HC Wainwright & Co. | → 25 美元 | 啓動覆蓋開啓 | → 購買 |
| 2021 年 4 月 13 日 | 7794.71% | B. 萊利證券 | → 21 美元 | 啓動覆蓋開啓 | → 購買 |
| 2021 年 3 月 17 日 | 9298.46% | 羅斯資本 | → 25 美元 | 啓動覆蓋開啓 | → 購買 |
What is the target price for GT Biopharma (GTBP)?
GT Biopharma（GTBP）的目標價格是多少？
The latest price target for GT Biopharma (NASDAQ: GTBP) was reported by EF Hutton on August 7, 2023. The analyst firm set a price target for $2.00 expecting GTBP to rise to within 12 months (a possible 651.88% upside). 8 analyst firms have reported ratings in the last year.
EF Hutton於2023年8月7日公佈了GT Biopharma（納斯達克股票代碼：GTBP）的最新目標股價。這家分析公司將目標股價定爲2.00美元，預計GTBP將在12個月內升至12個月內（可能上漲651.88％）。去年有8家分析公司公佈了評級。
What is the most recent analyst rating for GT Biopharma (GTBP)?
分析師對GT Biopharma（GTBP）的最新評級是多少？
The latest analyst rating for GT Biopharma (NASDAQ: GTBP) was provided by EF Hutton, and GT Biopharma reiterated their hold rating.
GT Biopharma（納斯達克股票代碼：GTBP）的最新分析師評級由EF Hutton提供，GT Biopharma重申了他們的持倉評級。
When is the next analyst rating going to be posted or updated for GT Biopharma (GTBP)?
GT Biopharma（GTBP）的下一個分析師評級何時公佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of GT Biopharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for GT Biopharma was filed on August 7, 2023 so you should expect the next rating to be made available sometime around August 7, 2024.
分析師在進行了廣泛的研究（包括瀏覽公開財務報表、與GT Biopharma的高管和客戶交談以及聽取業績電話會議）後得出股票評級。大多數分析師每三個月進行一次評級，因此每家公司每年應該獲得4個評級。GT Biopharma的最後一次評級是在2023年8月7日提交的，因此您應該預計下一個評級將在2024年8月7日左右公佈。
Is the Analyst Rating GT Biopharma (GTBP) correct?
分析師對 GT Biopharma (GTBP) 的評級正確嗎？
While ratings are subjective and will change, the latest GT Biopharma (GTBP) rating was a reiterated with a price target of $0.00 to $2.00. The current price GT Biopharma (GTBP) is trading at is $0.27, which is within the analyst's predicted range.
儘管評級是主觀的，而且會發生變化，但最新的GT Biopharma（GTBP）評級得到了重申，目標股價爲0.00美元至2.00美元。GT Biopharma（GTBP）目前的交易價格爲0.27美元，在分析師的預測區間內。